Holen Sie sich die Stockscreener-App
43.17
2.66%
1.12
Handel nachbörslich:
42.46
-0.71
-1.64%
Schlusskurs vom Vortag:
$42.05
Offen:
$41.88
24-Stunden-Volumen:
202.89K
Relative Volume:
0.51
Marktkapitalisierung:
$933.92M
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-4.7077
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
-1.80%
1M Leistung:
+11.98%
6M Leistung:
-43.91%
1J Leistung:
+4.81%
1-Tages-Spanne:
$40.93
$43.88
1-Wochen-Bereich:
$40.93
$44.40
52-Wochen-Spanne:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
43.17 | 933.92M | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
Trend Tracker for (PRAX) - news.stocktradersdaily.com
Praxis Precision Medicines (NASDAQ:PRAX) Given Buy Rating at Needham & Company LLC - Defense World
Needham Reiterates Buy Rating on Praxis Precision Medicine (PRAX) with $80 Price Target | PRAX Stock News - GuruFocus
Bank of America Corp DE Reduces Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
California State Teachers Retirement System Acquires 275 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Acquires 2,747 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Ameriprise Financial Inc. Buys Shares of 3,227 Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Day 8 of Gains Streak for Praxis Precision Medicines Stock with 23% Return (vs. -42% YTD) [6/6/2025] - Trefis
Weston investment banker pleads guilty to insider trading offense - Westfair Communications
Trading (PRAX) With Integrated Risk Controls - news.stocktradersdaily.com
Praxis Precision Medicines, Inc. Announces Inducement Grants Und - GuruFocus
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Praxis Precision Medicines Strengthens Talent Acquisition with New RSU Grant Program - Stock Titan
Can PRAX Rebound On Multiple Upcoming Epilepsy Trial Readouts? - RTTNews
Two Sigma Investments LP Lowers Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given a $97.00 Price Target at Oppenheimer - Defense World
Oppenheimer assigns outperform rating to Praxis Precision Medicines stock By Investing.com - Investing.com Canada
Oppenheimer Sets Price Target of $97 on PRAX with Outperform Rat - GuruFocus
Oppenheimer Sets Price Target of $97 on PRAX with Outperform Rating | PRAX Stock News - GuruFocus
Oppenheimer assigns outperform rating to Praxis Precision Medicines stock - Investing.com
Praxis Precision (PRAX) Gains Positive Outlook from Oppenheimer | PRAX Stock News - GuruFocus
Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Down 5.6% – Time to Sell? - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Stock Position Reduced by BNP Paribas Financial Markets - Defense World
(PRAX) Trading Report - news.stocktradersdaily.com
Deutsche Bank AG Buys 5,009 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Praxis Precision Medicines to Participate in Upcoming Conferences - GlobeNewswire
Praxis Precision Medicines to Participate in Upcoming Conferences | PRAX Stock News - GuruFocus
What is Chardan Capital’s Forecast for PRAX FY2025 Earnings? - Defense World
Dimensional Fund Advisors LP Decreases Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Northern Trust Corp Raises Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Investment Report - news.stocktradersdaily.com
Piper Sandler maintains Praxis stock at $270 target, bullish stance By Investing.com - Investing.com India
Praxis Precision Medicines (NASDAQ:PRAX) Research Coverage Started at Chardan Capital - Defense World
Praxis Precision Medicines (PRAX) to Release Earnings on Monday - Defense World
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analytical Lens: Exploring Praxis Precision Medicines Inc (PRAX)’s Financial Story Through Ratios - DWinneX
3,008 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Bought by Envestnet Asset Management Inc. - Defense World
Wedbush Has Positive Outlook for PRAX Q2 Earnings - Defense World
This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - NewsBreak: Local News & Alerts
HC Wainwright Issues Negative Forecast for PRAX Earnings - Defense World
Praxis Precision Medicines 'A Diversified Player In Epilepsy Market,' Analyst Sees Over 100% Stock Upside - Benzinga
Chardan Capital Initiates Coverage of Praxis Precision Medicines (PRAX) with Buy Recommendation - Nasdaq
Chardan Capital Initiates Coverage on PRAX with a Buy Rating | PRAX Stock News - GuruFocus
Chardan Initiates Praxis Precision Medicines at Buy With $80 Price Target - marketscreener.com
Chardan Initiates Coverage on Praxis Precision (PRAX) with Buy Rating | PRAX Stock News - GuruFocus
Analysts Issue Forecasts for PRAX Q4 Earnings - Defense World
HC Wainwright Has Bearish Forecast for PRAX FY2029 Earnings - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given New $28.00 Price Target at Wedbush - Defense World
Analysts Offer Insights on Healthcare Companies: Cerus (CERS), Stryker (SYK) and Praxis Precision Medicines (PRAX) - The Globe and Mail
Praxis Precision Medicines (NASDAQ:PRAX) Receives “Buy” Rating from Needham & Company LLC - Defense World
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Praxis Precision Medicines Inc-Aktie (PRAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Nemiroff Alex | General Counsel and Secretary |
Nov 14 '24 |
Sale |
80.20 |
8,239 |
660,827 |
10,301 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Option Exercise |
56.94 |
4,374 |
249,056 |
10,801 |
| Mastrocola Lauren | Principal Accounting Officer |
Nov 14 '24 |
Sale |
81.78 |
5,188 |
424,318 |
5,613 |
0.39%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):